ABSTRACT: The purpose of study was to investigate the maturation of mesenchymal stem cells (MSC) laden in HA constructs with various combinations of chemically defined medium (CM) components and determine the impact of dexamethasone and serum on construct properties. Constructs were cultured in CM with the addition or withdrawal of media components or were transferred to serum containing media that partially represents an in vivo-like condition where pro-inflammatory signals are present. Constructs cultured in CMþ (CM with TGF-b3) and DEXÀ (CMþ without dexamethasone) conditions produced robust matrix, while those in ITS/BSA/LAÀ (CMþ without ITS/BSA/LA) and Serumþ (10% FBS with TGF-b3) produced little matrix. While construct properties in DEXÀ were greater than those in CMþ at 4 weeks, properties in CMþ and DEXÀ reversed by 8 weeks. While construct properties in DEXÀ were greater than those in CMþ at 4 weeks, the continued absence or removal of dexamethasone resulted in marked GAG loss by 8 weeks. Conversely, the continued presence or new addition of dexamethasone at 4 weeks further improved or maintained construct properties through 8 weeks. Finally, when constructs were converted to Serum (in the continued presence of TGF-b3 with or without dexamethasone) after pre-culture in CMþ for 4 weeks, GAG loss was attenuated with addition of dexamethasone. Interestingly, however, collagen content and type was not impacted. In conclusion, dexamethasone influences the functional maturation of MSC-laden HA constructs, and may help to maintain properties during long-term culture or with in vivo translation by repressing pro-inflammatory signals. ß
Strategies to engineering cartilaginous tissues using mesenchymal stem cells (MSCs) are promising given that these multipotent cells can undergo chondrogenesis in a variety of 3D contexts. [1] [2] [3] [4] [5] Particularly, MSCs in hyaluronic acid (HA) hydrogels 1, [6] [7] [8] [9] [10] produce robust matrix equivalent to that produced by chondrocytes, when cultured in a chemically defined medium (CM) supplemented with TGF-b3 (CM þ ). 2, [11] [12] [13] Building from the initial description of the CM formulation that supports chondrogenesis, 12, 14 a number of studies have explored which components are absolutely necessary, and over what time course. For instance, using both chondrocytes and MSCs, several studies have shown that transient inclusion of TGF-b3 with a very high dose (100 ng/ml) in CM over a relatively short period (<2 weeks) results in greater properties than continual exposure to TGFb3 with a low dose (10 ng/ml). 2, [15] [16] [17] Translating this finding, others have shown that alginate-coated TGFb3 microspheres co-encapsulated with human MSCs in HA hydrogels resulted in robust chondrogenesis. 18 While these are compelling findings, the transition to the in vivo environment may be more complicated, especially when the in vivo environment is the synovial joint. Successful strategies for cartilage repair require not only fabrication of an engineered construct with native properties, but also stability of these properties within the native load-bearing synovial environment. Synovial fluid is a dialysate of the blood that is comparable to serum, and additionally contains HA, lubricin, proteinases, collagenases, and occasionally lymphocytes, monocytes, neutrophils and serum proteins 19 including albumin, immunoglobulin, transferrin, fibrinogen, macroglobulin, antitrypsin, haptoglobin, glycoprotein, and apolipoprotein. Recently, we showed that when MSC-laden constructs were transferred to serum containing media at the time of TGF withdrawal, construct properties rapidly decreased with marked GAG loss. 17 This suggests that while CMþ can foster maturation, conflict signals present in serum and synovial fluid may compromise long term functionality, and so may limit clinical translation.
One additional factor in CM, dexamethasone (DEX), is a synthetic glucocorticoid known to have pro-chondrogenic 11, 14 and anti-inflammatory effects. 20, 21 Dexamethasone suppresses inflammatory signaling (e.g., IL-8 secretion regulated by p38MAPK, AP-1, and NF-kB activity). 22 A recent study also showed that glucocorticoid combined with HA enhances glucocorticoid receptor activity to inhibit activation of the p38 MAPK signaling pathway. 23 Interestingly, several studies have shown that dexamethasone is an indispensable component in CM. 11, 14 One recent combinatorial screen coupled with RNA profiling showed that dexamethasone acted synergistically with TGF-b to promote MSC chondrogenesis. 24 In another recent study, however, it was shown that dexamethasone inhibits BMP-2 induced MSC chondrogenesis, and that removal of dexamethasone in CM improved GAG deposition in synovial explants. 25 In chick limb bud cultures, the dose of dexamethasone played a role, where lower doses improved chondrogenesis and higher doses promoted osteogenic conversion. 26 Similarly, others have reported a different impact of dexamethasone in young bovine and adult human MSCs in agarose and selfassembling peptide hydrogels. 20 Further, in shortterm cultures of equine MSCs in agarose hydrogels, withdrawal of dexamethasone had an adverse impact on matrix accumulation when this factor was absent for longer than 2 days. 27 Collectively, these data suggest there are species, age, cell source, material context, and time dependent effects of dexamethasone on MSCs and progenitor cell chondrogenesis.
Given these findings, the goal of this study was to investigate the effect of dexamethasone in longterm cultures of MSCs in hydrogels, both in CM and under "conflict" conditions wherein the constructs were transferred to a more in vivo-like serum containing setting. In a first set of studies, we investigated the maturation of MSC-laden constructs with various combinations of media components that make up CM, with a particular focus on dexamethasone and serum substitutes (e.g., ITSþ Premix) and the presence of serum. In a subsequent study, based on the differential effect of dexamethasone on functional properties during the culture period, we examined the short and long term effect of dexamethasone presence and absence in CM. Finally, given that previous studies indicated an anti-inflammatory role for dexamethasone, we assayed its role in attenuating matrix disruption when constructs were transferred to serum containing "conflict" media for extended culture.
METHODS
Preparation of Cell/Tissue Culture Media Basal media (BM), CM, or media with addition/removal of CM components were prepared as outlined in Table 1 . BM consisted of high glucose DMEM with 10% FBS (Gibco, Grand Island, NY) and 1% penicillin/streptomycin/fungizone (PSF)(Gibco). This media was used to isolate and expand MSCs. CM contained high glucose DMEM with 1Â PSF, 0.1 mM dexamethasone, 50 mg/ml ascorbate 2-phosphate, 40 mg/ml L-proline, 100 mg/ml sodium pyruvate, 6.25 mg/ml insulin, 6.25 mg/ml transferrin, 6.25 ng/ml selenious acid (namely ITS), 1.25 mg/ml bovine serum albumin (BSA), and 5.36 mg/ml linoleic acid (LA). This CM was further supplemented with 10 ng/mlL TGF-b3 (R&D Systems, Minneapolis, MN) to produce a chondrogenic induction media. To identify the effect of the specific media components in CMþ, additional formulations were developed including DEXÀ (removal of dexamethasone from CMþ), ITS/BSA/LAÀ (removal of serum substitute from CMþ), or Serumþ (addition of serum and removal of dexamethasone and ITS/BSA/LA) ( Table 1 ).
Preparation of Mesenchymal Stem Cells
MSCs were isolated from juvenile bovine knees from three different donors (Research 87, Bolyston, MA). To extract bone marrow, cubes of trabecular bone were segmented from the epi-and metaphyseal region of the femur and tibia and were washed with medium containing 0.2% heparin (SigmaAldrich, St. Louis, MO). The diluted bone marrow was pooled and washed in BM, resuspended and plated onto tissue culture plastic. Adherent cells were noted within 5 days, and were expanded to passage 3 to obtain sufficient cell numbers for hydrogel encapsulation.
MeHA Synthesis
Synthesis of methacrylated hyaluronic acid (MeHA) was as previously described by Burdick et al. 7 Briefly, 1% w/v sodium hyaluronate (65 kDa MW; Lifecore, Chaska, MN) dissolved in deionized water was reacted with methacrylic anhydride (Sigma-Aldrich) on ice at a pH of 8.0 with 5 N NaOH (Sigma-Aldrich) for 6 h. This was followed by dialysis (No.132670, 6 kDa MWCO, Spectrum Laboratories, Rancho Dominguez, CA) to remove unreacted byproducts for 1 week with repeated changes of distilled water. The MeHA solution was lyophilized and stored at À20˚C. 
MSC Encapsulation and Construct Culture
To form gels, lyophilized MeHA was dissolved at 1% w/v in PBS with 0.05% w/v photoinitiator (Irgacure I2959, Ciba-Geigy, Tarrytown, NY). MSCs were resuspended at a concentration of 60 million cells/ml and poured into a gel casting apparatus (Hoefer, Inc., Hollison, MA) 28 and exposed to UV using a 365 nm Blak Ray UV lamp (UVL-56, San Gabriel, CA) for 10 min. The range of the UV was 320-400 nm with a transmission maximum of 70% at 365 nm. To explore the effect of media components in chondrogenic maturation of MSCs laden in HA hydrogels, cylindrical constructs (Ø4 Â 2.25 mm) were cored using a biopsy punch from the resulting hydrogel slabs and cultured in CMþ, DEXÀ, ITS/BSA/LAÀ, or Serumþ for 8 weeks ( Table 1 ). Each construct received 2 ml of media, which was changed thrice weekly for the duration of the study.
Effect of Dexamethasone on Construct Maturation
To explore the short and long-term effects of DEX inclusion or exclusion, MSC-laden HA constructs were cultured in CMþ (the C group) for 4 weeks, and then were maintained in CMþ (the C-C group) or were transferred to DEXÀ (the C-D group; removal of dexamethasone from CMþ) for the next 4 weeks. Likewise, constructs cultured in DEXÀ (the D group) for the first 4 weeks were converted to CMþ (the D-C group) or were continuously cultured in DEXÀ (the D-D group) through 8 weeks (Fig. 2B) . The level and timing of GAG, collagen, and nitrite released from constructs during the culture period were assessed using supernatants collected from each media change.
Effect of Dexamethasone in Serum Containing Media
Early results showed that transfer of constructs from CMþ to serum containing media resulted in rapid loss of mechanical properties. To assess whether dexamethasone could inhibit GAG loss in the context of serum containing media, constructs were first cultured for 4 weeks in CMþ or Serum with or without dexamethasone and/or TGF (TGFÀ/DEXþ, TGFþ/ DEXÀ, or TGFþ/DEXþ) (Fig. 4A ). Constructs cultured in Serum were harvested at 4 weeks, while constructs maintained in CMþ for the first 4 weeks were either continuously cultured in CMþ (CMþ_CMþ) or were converted to BM with or without dexamethasone (TGFþ/DEXÀ or TGFþ/DEXþ) for the next 4 weeks.
Cell Viability
Cell viability was assessed using the LIVE/DEAD staining kit (Molecular Probes, Invitrogen, Eugene, OR), and was determined by calcein AM and ethidium homodimer, respectively.
Analysis of Mechanical Properties
Unconfined compression testing was performed to determine bulk compressive equilibrium (E Y ) and dynamic (|G Ã |) moduli of constructs as in Mauck et al. 28, 29 Compressive modulus was determined via a stress-relaxation test including a step compression at 0.05%/s to 10% strain after creep loading to 0.02 N for 5 min. The relaxation phase was for 1,200 s. Subsequently, a 1% sinusoidal deformation was applied at 1.0 Hz to obtain the dynamic modulus. Prior to mechanical testing, the top and bottom surfaces of constructs were carefully planed using a freezing stage microtome to ensure an even contact surface.
Biochemical Analysis
After mechanical testing, construct wet weight was measured followed by papain digestion. Sulfated glycosaminoglycan content was assessed using the 1,9-dimethylmethylene blue assay. 30 Orthohydroxyproline (OHP) content was measured via reaction with chloramine T and diaminobenzaldehyde. Collagen content was extrapolated from OHP using a 1:7.14 ratio of OHP. 31 In some studies, GAG, collagen, nitrite (Griess Reagent System; Promega, Madison, WI), 32 and MMP activity (SensoLyte 520 Generic MMP kit; AnaSpec, Fremont, CA) was assessed using media supernatants collected at each media change over the culture period.
Histological Analysis
Constructs were fixed in 4% paraformaldehyde for 24 h and embedded in paraffin. Sections (8 mm) were deparaffinized in a graded series of ethanol and stained with Alcian Blue (pH 1.0) for proteoglycans (PG). Immunohistochemistry was carried out to visualize types I, II, and X collagen using IHC Select HRP/DAB kit (Millipore, Billerica, MA). Primary antibodies to type I collagen (MAB3391; Millipore), type II collagen (II-II6B3; DSHB, Iowa City, IA), and type X collagen (X-AC9; DSHB) were used for immunolabeling.
Statistical Analysis
Statistical analysis was performed using the SYSTAT software (v10.2, SYSTAT software Inc., San Jose, CA). Significance was determined by two-way ANOVA with Tukey's post hoc test (p < 0.05).
RESULTS

Influence of Media Components on the Functional
Maturation of MSC-Laden HA Hydrogel Constructs Four media conditions were initially screened (Table 1) . MSCs were viable only in CMþ and DEXÀ ( Supplementary Fig. S1 ); constructs in these viable conditions maintained their initial shape and produced robust matrix (Fig. 1A) . Conversely, cells in ITS/BSA/ LAÀ and Serumþ did not remain viable, and these constructs contracted significantly over the culture period. Constructs cultured in Serumþ contracted very quickly, MSCs appeared to aggregate centrally, and this culminated in the formation of a central pellet-like structure that separated from the HA hydrogel. Equilibrium modulus (E Y ) and GAG content of constructs in CMþ and DEXÀ reached to 181 kPa (3.1%WW) and 296 kPa (4.2%WW) at 4 weeks, respectively, while the constructs in ITS/BSA/LAÀ and Serumþ had no measurable mechanical properties and lower GAG content (1.1 and 1.5%WW, respectively) ( Fig. 1A and B (Fig. 1C) . Similarly, Alcian blue staining showed marked PG production in constructs cultured in CMþ and DEXÀ at 4 weeks compared to ITS/BSA/LAÀ and Serumþ. However, PG accumulation of constructs in DEXÀ decreased after 8 weeks. (Fig. 1D) . Conversely, immunohistochemistry showed positive staining of type II collagen for all groups except for BMþ. The production of type II collagen was independent of addition and/or removal of dexamethasone and/or ITS/BSA/LA. Moreover, in the presence of TGF-b3, all groups showed little staining for types I or X collagen, regardless of the variations in PG and type II collagen (Fig. 1E-G) .
Short and Long-Term Effects of Dexamethasone on Construct Maturation
Given that dexamethasone seemed dispensable in the first period of culture, we next carried out a study exploring the timing of exposure. Withdrawal (the C-D group) or continued absence (the D-D group) of dexamethasone reduced viability near the peripheral region (Supplementary Fig. S2 ). The mechanical properties and GAG content of constructs in the DEXÀ (267 kPa and 3.5%WW) were greater than these in CMþ (198 kPa and 3.1%WW) at 4 weeks ( Fig. 2B and C, and Table 3 ). However, when continuously cultured in DEXÀ, construct properties decreased by 8 weeks (25 kPa; p < 0.0001 ROLE OF DEXAMETHASONE IN MSCs and 1.6%WW; p < 0.0001, respectively). Likewise, when constructs cultured in CMþ were switched to DEXÀ, construct properties markedly decreased (25 kPa; p ¼ 0.008 and 1.5%WW; p < 0.0001, respectively) by 8 weeks. However, constructs that were continuously cultured in CMþ or were switched to CMþ after the first 4 weeks of culture in DEXÀ slightly increased or maintained their properties (290 kPa and 4.1%WW (p ¼ 0.009) for the C-C group and 285 kPa and 3.6%WW for the D-C group). Collagen content was also independent of the addition or removal of dexamethasone, generally increasing with culture duration (Fig. 2D) . Alcian blue staining showed robust PG deposition in CMþ and DEXÀ after 4 weeks, with greater intensity in the peripheral region compared to the core. Constructs continuously cultured or switched to CMþ accumulated intense ECM and PCM in the periphery and core regions, whereas those cultured or switched to DEXÀ decreased in PG content, particularly in the peripheral region (Fig. 2E ). GAG and nitrite release from constructs increased with the switch to DEXÀ (at week 4) and continued to increase over the next 3 weeks whereas constructs maintained in CMþ showed a lower release of both ( Fig. 2F and G) . The amount of collagen released from constructs was similar and steady for all groups (data not shown). Immunostaining showed a peripheral region with greater type II collagen staining compared to the center, but the matrix intensity was similar for all groups regardless of presence or partial/continuous absence of dexamethasone (Fig. 3A) . No staining for types I or X collagen matrix was observed ( Fig. 3B and C (Fig. 4C) . Consistent with the results from the first and second study, collagen content did not change on a per wet weight basis (Fig. 4D) . GAG release from constructs occurred almost immediately when converted to Serum, and lasted through the culture duration. GAG loss in Serum supplemented with dexamethasone was slightly lower (Fig. 4F) . MMPs released to the media were similar to GAG, with no pronounced effect of dexamethasone (MMP level in BM: 5 mM) (Fig. 4G ). Nitrite and collagen release (data not shown) showed no changes, and cells remained viable for all groups even after conversion to Serum (Supplementary Fig. S3 ). Alcian blue staining showed that constructs cultured in Serum produced little to no matrix and showed marked contraction (left column). Constructs in CMþ grew well and produced robust matrix with time in culture (middle). However, when the constructs were switched to Serum, GAG loss was partially inhibited for constructs in the presence of dexamethasone, whereas constructs switched to Serum in the absence of dexamethasone showed marked GAG depletion (Fig. 4H) . Similarly, constructs cultured in Serum in the presence of TGF (Tþ/DÀ or Tþ/Dþ; left column) produced some positive staining for type II collagen, but also showed some positive staining for types I and X collagen (Fig. 5) . Constructs in 
DISCUSSION
In this study, we determined the roles of various CM components on the chondrogenesis and functional maturation of MSCs-laden constructs. Further, we defined the role of dexamethasone during culture in these CM conditions and after transition of constructs to a conflicting (in vivo-like) environment that contained serum. Our findings show that MSC-laden constructs produce robust matrix in CMþ, and that mechanical properties and GAG content were greater in DEXÀ after 4 weeks. However, we also noted that with the prolonged absence of dexamethasone, the mechanical properties and GAG content of these constructs markedly decreased by 8 weeks, whereas those constructs cultured in CMþ for entire period showed persistent increases throughout this time period. This indicates that dexamethasone plays a key role in regulating pro-chondrogenic and antiinflammatory activities, consistent with previous studies, 11, 20 and supports long-term tissue formation and maturation.
Our data also showed that no matrix was produced when constructs were cultured from the outset in ITS/ BSA/LAÀ or in Serumþ. ITS/BSA/LA include essential components in CM, namely insulin, transferrin, selenium, bovine serum albumin (BSA), and linoleic acid, [33] [34] [35] and is commonly used as a serum replacement (i.e., ITS Premixþ) to improve consistency of in vitro studies. Insulin is crucial for glucose transport into cultured cells, and transferrin is an ion carrier. Selenium, as sodium selenite, is a cofactor for selenium-dependent enzyme activities (e.g., glutathione reductase, glutathione peroxidase), and inhibits oxidation. Linoleic acid is a precursor of prostaglandins, glycolipids, and vitamins, while albumin serves as a plasma substitute for the growth of cultured cells. The poor growth of constructs in ITS/BSA/LAÀ indicate that these molecules are imperative for growth in CM. This indicates that some serum elements (i.e., transferrin and insulin) are essential for construct growth, but that other elements in serum can limit matrix formation by MSCs. Based on our observation of a differential effect of dexamethasone on functional maturation during the culture period, we further investigated how dexamethasone regulated functional properties with time in culture. Consistent with previous results, constructs produced greater mechanical properties and GAG content in the absence of dexamethasone through 4 weeks, compared to constructs cultured in the presence of dexamethasone. However, constructs cultured with the continuous absence of dexamethasone showed a marked decrease in properties by 8 weeks compared to those with the continuous addition of dexamethasone. Interestingly, when dexamethasone was added later in culture, construct properties were maintained through the 8 weeks. Conversely, when dexamethasone was withdrawn at 4 weeks, construct properties decreased to the level of the continuous absence of dexamethasone. This suggests that the presence of dexamethasone is essential during the latter phases of construct maintenance, but may not be necessary during the rapid growth phase of construct maturation.
These mechanical and biochemical analyses were largely confirmed by histological assessment, which also showed that constructs with continuous addition of dexamethasone or with dexamethasone added later retained a dense matrix in both peripheral and central regions. Conversely, the removal or absence of dexamethasone resulted in marked depletion of GAG, with greater loss in the peripheral region. Analysis of loss of GAG and nitrite content (indicative of inflammation) in media showed that all groups had low levels, regardless of the presence of dexamethasone, at 4 weeks. Later, however, levels of both indicators of a catabolic state gradually increased for constructs cultured without dexamethasone, while release of GAG and nitrite production by constructs with dexamethasone remained lower. These data suggest that constructs produce greater properties in the absence of dexamethasone over the short-term (through week 4), but require dexamethasone to retain these properties over longer durations (through week 8), as shown in the first study. Given the finding of increased nitrite in media over this period, the role of dexamethasone during this period may arise from the state of cells after maturation is complete. It has been reported that IGF-1 signaling, which maintains cartilage homeostasis in healthy cartilage, is sensitive to nitric oxide (NO). The presence of NO decreases IGF receptor expression and makes cartilage insensitive to the anabolic effects of IGF-1. 36, 37 This effect of NO was enhanced when glutathione (an anti-oxidant) was depleted from the media. 36 This implies that reactive oxygen species that arise during long-term culture (due to an increase of oxidative stress) may be mitigated by the action of dexamethasone, making this factor essential for the stability of MSC-based engineered cartilage cultured in vitro for long periods.
Based on the finding that dexamethasone is essential for the long term stability of chondrogenic MSCbased constructs, we next queried the potential protective role of this factor when constructs were transferred to in vivo like conditions including serum, a "conflict" signal. Constructs cultured from the outset in serum containing media, with or without dexamethasone, failed to mature, and produced no matrix. However, when constructs were pre-cultured in CMþ for 4 weeks, and then converted to serum containing media, dexamethasone had a positive effect on longterm outcomes. That is, while all constructs lost mechanical properties compared to their week 4 values in serum containing media, GAG loss was attenuated with dexamethasone (34% loss compared to 80% loss without dexamethasone at 8 weeks). Interestingly, GAG release after transfer to serum containing media occurred very rapidly, reaching a maximum in 1 week. Collagen content was largely unaffected in the absence of dexamethasone, but constructs cultured or transferred to Serum showed inferior staining and/or some depletion of type II collagen, suggesting that collagen synthesis and maturation may be influenced by catabolic elements in serum. Since synovial fluid contains serum elements and other factors, the response of MSC-laden constructs in serum may not fully reflect 
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those to synovial fluid. Despite this, our results clearly showed an effect of serum components in the production and maturation of matrix. When constructs were transferred to Serum, released GAG and MMPs in the media increased. Since measured MMP activity in Serum (10% FBS) is low (5 mM), this implies that MMPs secretion by cells was induced by the addition of serum.
While the literature on the effect of dexamethasone offer diverse findings, 20, 24, 25, 27 results from our study and many others suggest that dexamethasone supports matrix accumulation, especially combined with growth factors (e.g., TGF-b3), and suppresses matrix catabolism. This suggests that delivery of dexamethasone could be optimized to sustain construct properties by systemic or local delivery postconstruct implantation, and that the timing and concentration of this delivery should be considered. 25, 27 Since local delivery of dexamethasone may be required, it is auspicious that numerous methods to deliver dexamethasone and other growth factors have been introduced for cartilage repair. For example, early work by Nuttelman and co-workers, 38 generated dexamethasone-releasing poly(ethylene glycol) (PEG)-based hydrogels, where dexamethasone was covalently linked to a photo-reactive PEG molecule via a degradable lactide bond. This allowed for sustained release of dexamethasone with in vivo hydrolysis of the ester bond. Other work, by Na et al., 39, 40 fabricated a thermo-reversible hydrogel using poly(NiPAAm-co-AAc) as an injectable drug delivery vehicle with co-encapsulated dexamethasone and TGF-b3. Similarly, local dual delivery of dexamethasone/TGF-b3 via with heparin in or on PLGA microspheres has been demonstrated to promote rabbit MSC chondrogenesis. 41 Most recently, Roach et al., 42 demonstrated delivery of dexamethasone via PLGA microspheres in a chondrocyte-laden agarose hydrogel. Kopesky et al., 43 utilized a self-assembled peptide hydrogel (i.e., AcN-(KLDL) 3 -CNH 2 ) encapsulated with TGF-b1 for sustained delivery of TGF-b1. Jung et al., 44 introduced monoCB [6] /DAH-HA (monofunctionalized cucurbit [6] uril-HA (CB [6] -HA), diamino-hexane conjugated HA (DAH-HA), and drug conjugated CB [6] (drug-CB [6] )) for controlled chondrogenesis of human MSCs. Finally, Bajpayee et al., 45, 46 introduced avidin for charge based intraarticular delivery of a single dose of dexamethasone, and demonstrated that this single dose was both quickly and slowly released.
Collectively, our findings support the importance of dexamethasone in improving and maintaining functional MSC chondrogenesis in HA hydrogels. Targeted delivery and controlled release of dexamethasone (and TGF-b3) and recent advances in drug delivery systems to enable their release, may enable successful cartilage repair with MSC-based constructs by controlling tissue homoeostasis and promoting long term function after implantation.
